Paclitaxel Injection
Product Images NDC 46708-621

This appears to be a survival analysis table that shows the proportion surviving over time. The table has four rows for each year (1-4 years), with columns listing the number at risk for each group (T, C, and 0), the number of events, and the hazard ratio with 95% confidence interval. Unfortunately, without more context or information about the study, it is difficult to interpret the results.*

This appears to be a survival analysis report. It provides the proportion surviving, number of events, hazard ratio, and number at risk for two groups (Te vs. N) over a span of four years. The HR value suggests that the risk of the event occurring in N is higher than that in Te.*

This appears to be a table displaying the proportion of disease-free individuals over a certain period of time for different treatments (AC and AC+T) and the number of events (disease occurrences) for each group. The table also includes the hazard ratio (HR) and the confidence interval (95% CN) for AC+T compared to AC only. The number at risk for each group is also provided. The text covers a graph, but it seems that the x-axis represents years.*

This is a statistical report presenting the proportion surviving for two different groups denoted by "AC+T" and "AC AT". The report contains information about the total number of individuals in each group, the number of events (such as deaths) observed, hazard ratio with confidence interval, and a table looking at the number of individuals at risk over time. This table shows the number of individuals in each group at different time points (0, 1, 2, 3 and 4 years).*

This appears to be a statistical table related to disease-free proportions and the effectiveness of certain treatments (AC+T and AC) over a period of 4 years. The table includes information about the number of events, hazard ratio, and 95% confidence interval. However, without additional context or information, it is difficult to provide a more specific description or analysis of the data.*

This is a report on cancer treatment (AC+T and AC) and probability of disease-free survival over a period of 4 years, observed through the number of events (cancer occurrence) and hazard ratio. However, no further information is available due to the limited text.*

This appears to be a table with information related to a clinical trial or medical study. It shows the number of participants (N) and the number of events (No. events) observed in a group, as well as a hazard ratio (HR) and confidence interval (Cl) for the proportion of the group that remained disease-free. It also includes a breakdown of the number of participants at risk for each year (0-4). Without further context or information, it is difficult to provide more specific details or interpretation.*

This is a statistical report presenting information about the duration of a medical treatment and its effectiveness in preventing the recurrence of a disease. The treatment in question is compared to another one referred to as "JAC". The report shows the number of disease-related events observed during a follow-up period of 4 years in two groups of patients, one receiving the AC+T treatment and the other the JAC treatment. The proportion of patients who remained disease-free in each group is illustrated graphically by the numbers at risk. The AC+T treatment is shown to have a higher proportion of disease-free patients than JAC. The Hazard Ratio (HR) is 0.73, indicating a 27% reduction in risk of developing the disease with AC+T.*

This is a description of a medication called "Paclitaxel Injection, USP". It comes in a container with a 100mg/16.7mL dosage and needs to be diluted prior to intravenous infusion. It is a cytotoxic agent and must be stored between 20-25°C. The prescription is protected from light and is only available through a prescription from a doctor.*

This is a description of a medication called "Semisynthetic Paclitaxel Injection, USP". It is sold in packs containing 57,527 mg of the medication and is available in a 300mg/50mL solution. It is a cytotoxic agent and should be used with caution, with a prescription from a doctor. The product requires proper handling and storage between temperatures of 2-35 degrees Celsius. The provided text also contains warnings and instructions which should be followed to avoid any side effects or harm.*

This is a description of a drug called Paclitaxel, which is available in the form of an injection. The drug comes in semisynthetic form with a volume of 30 mg/5 ml and 6 mg/ml. The text provides instructions on how to use and store the drug. It mentions that the drug is only available on prescription and requires caution when using. There is also a warning about the risk of intravenous use.*

Paclitaxel Injection is a cytotoxic agent used for intravenous infusion. Each mL contains 6 mg of paclitaxel, 527 mg of Polyoxyl 35 Castor Oil, 49.7% Dehydrated Alcohol, and 2 mg Citric Acid. The drug should be handled with gloves and the container should be retained in the carton until use. The recommended storage temperature is between 20° to 25°C. The injection is sold in a 16.7 mL multiple-dose vial and requires dilution before use. The manufacturer of Paclitaxel Injection is Alembic Pharmaceuticals Limited located in Gujarat, India. No English translation is available for the unintelligible characters.*

Paclitaxel Injection is a cytotoxic agent used for intravenous infusion. The vial contains 6mg of Paclitaxel, along with 527mg of Polyoxyl 35 Castor Oil, 49.7% Dehydrated Alcohol, and 2mg Citric Acid per mL. It is necessary to wear gloves when handling containers. Dosage information is provided in the insert, and it should be stored between 20-25°C. The product should be protected from light. The vial is manufactured by Alembic Pharmaceuticals Limited, located in Gujarat, India. Dilution is required before intravenous infusion. The provided lot number is unreadable.*

This is a medication called Paclitaxel Injection, which is available only by prescription. Each container contains 6mg of Paclitaxel and 527mg of Semisynthetic Polyoxy135 Castor Oil. It is manufactured by Alembic Pharmaceuticals Limited in India and requires dilution before use. The recommended storage temperature is between 20°C to 25°C, and a warning label cautions users that this medication is a cytotoxic agent. The packaging also includes a lot number. Dosage instructions are provided in the insert. Gloves must be worn when handling containers, and the medication must be protected from light.*